NCT07722611
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 5 → 8 locations
- Minor Trial sites expanded: 1 → 5 locations
- Start date changed from estimate of Oct 21, 2026 to Oct 29, 2026
- Minor Study sites: 1 to 2
- Minor Start date pushed from Oct 7, 2026 to Oct 21, 2026
- Study title revised
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 17 words
- Study sites: 0 to 1
- Start date: Sep 21, 2026 to Oct 7, 2026
- Secondary endpoints: details revised at 11 of 12 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
Participants will receive bomedemstat daily for up to approximately 52 weeks. Per protocol, dosage may be adjusted within specified time parameters for each participant to achieve and maintain protocol-specified platelet and hematocrit target ranges. Eligible participants who do not discontinue study treatment at Week 52, may continue to receive study treatment.
Participants will receive either ropeinterferon alfa-2b or ruxolitinib as determined by investigator. All participants will be treated per respective approved product labels for up to approximately 52 weeks.
Drugs: Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b
Sites
8 sites in 3 countries
United States 4, Israel 3, Canada 1